BLU-701 + osimertinib

BLU-701 + osimertinib is an investigational oral combination therapy under clinical development for patients with EGFR-mutant non-small cell lung cancer (NSCLC), particularly for those harboring activating EGFR mutations (exon 19 deletion, L858R) and acquired resistance mutations, including C797X. BLU-701 is a fourth-generation, reversible, highly selective, wildtype-sparing, brain-penetrant EGFR tyrosine kinase inhibitor (TKI), designed to overcome known resistance to earlier EGFR TKIs. Osimertinib is a third-generation, irreversible EGFR TKI approved for EGFR-mutant NSCLC, targeting both activating and T790M resistance mutations. The combination is designed to enhance inhibition of heterogeneous tumor populations and prevent or overcome resistance, with activity including CNS metastases.

Other names

BLU-701BLU701BLU 701TAGRISSO